Segment Information

3 Months Ended

Sep. 26, 2015

Segment Reporting [Abstract]

Segment Reporting Disclosure [Text Block]

SEGMENT INFORMATION

Our reporting segments are as follows:

• CHC is focused primarily on the global sale of OTC store brand products including cough, cold, and allergy products, gastrointestinal products, analgesics, nicotine-replacement therapy ("NRT"), Vitamins, Minerals and Supplements ("VMS"), animal health products, infant formula and foods, and diagnostic products.

• BCH develops, manufactures, markets and distributes some of Europe's most well-known OTC brands in the natural health and VMS, cough, cold and allergy, NRT, personal care and derma-therapeutics, lifestyle, and anti-parasite categories.

• Rx develops, manufactures and markets a portfolio of generic and specialty pharmaceutical prescription drugs primarily for the U.S. and U.K. markets.

• Specialty Sciences is comprised primarily of royalties received from assets focused on the management of multiple sclerosis (Tysabri^®).

We also have an "Other" segment comprised of our active pharmaceutical ingredient ("API") business, which develops, manufactures, and markets active API used worldwide by both generic and branded pharmaceutical companies.

The below tables show select financial measures by reporting segment (in millions):

	Three Months Ended							Balance at September 26, 2015
	September 26, 2015
	Net Sales		Operating Income (Loss)			Amortization of Intangibles		Total Assets
CHC	$	675.2	$	117.3		$	19.4	$	4,211.2
BCH	302.2		4.4			36.3		6,728.0
Rx	260.3		91.0			18.6		2,597.6
Specialty Sciences	84.5		9.0			72.8		5,920.8
Other	22.5		6.2			0.5		245.5
Unallocated expenses	—		(39.3		)	—		—
Total	$	1,344.7	$	188.6		$	147.6	$	19,703.1

	Three Months Ended							Balance at June 27, 2015
	September 27, 2014
	Net Sales		Operating Income (Loss)			Amortization of Intangibles		Total Assets
CHC	$	640.3	$	74.8		$	16.2	$	4,381.6
BCH	—		—			—		6,441.1
Rx	194.5		64.7			17.0		2,667.9
Specialty Sciences	91.9		14.9			72.8		5,979.0
Other	24.8		7.1			0.5		251.0
Unallocated expenses	—		(24.3		)	—		—
Total	$	951.5	$	137.2		$	106.5	$	19,720.6